Real-world evidence of lower-dose intensity of immune checkpoint inhibitors in MSI-H/dMMR gastrointestinal cancers from a resource-constrained setting
Artículo
Acceso abierto
Artículo
DOAJ
BackgroundImmune checkpoint inhibitors (ICIs) have markedly improved outcomes in metastatic microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) gastrointestinal (GI) malignancies. However, in frag...
LCC TENDOk5lb3BsYXNtcy4gVHVtb3JzLiBPbmNvbG9neS4gSW5jbHVkaW5nIGNhbmNlciBhbmQgY2FyY2lub2dlbnM~Idioma eng
Acceso abiertoRuta libre sin proxy. Acceso recomendado cuando no hay suscripción activa.
Open Access